EN DE

Hantech Bio-Technology Co (1294) Fair Value & Analysis

Consumer Defensive · TW · Market cap 2.0B TWD

HB Hantech Bio-Technology Co 1294 · TWO
Price58.10 TWD
Fair Value72.52 TWD
Upside+24.8%
Quality62/100
Watch Hantech Bio-Technology Co for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Solidly profitable · 18.0% net margin
Low debt · generates free cash flow
4.43% dividend yield
Ranks above peers (10/14)
Wide moat 71/100
Evidence: High Range 53.58 TWD – 91.46 TWD Share as image

Fair value as of: Jul 23, 2026

From 26 valuation models · updated 18 days ago

Fair value updated Jul 23, 2026, revised from 87.02 TWD to 72.52 TWD (−16.7%) since Jul 7, 2026. Share price −1.5% over the past month.

A solid business, screening 25% undervalued on our models.

What matters now

  • Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality.
  • Our model range runs from 53.58 TWD (bear) to 91.46 TWD (bull), base 72.52 TWD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 62/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (4 years)

483.55 TWD 19.23 TWD Fair Value 72.52 TWD Sep 2022 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

46‑month range 19.23 TWD – 483.55 TWD · fair‑value band 53.58 TWD – 91.46 TWD · the 58.10 TWD price screens below the 72.52 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Hantech Bio-Technology Co (1294) currently trades at 58.10 TWD, while our model-based Fair Value estimate is 72.52 TWD, implying the stock looks roughly 24.8% undervalued today. The Quality Score stands at 62/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Hantech Bio-Technology Co generated revenue of 832M TWD at a net margin of 18.0%. Revenue grew 30.6% year over year. It earns a return on equity of 17.6%. Net debt stands at 118M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 53.58 TWD (bear case) to 91.46 TWD (bull case); at 58.10 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -3% fair-value upside, at 25%, 1294 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 64.13 TWD 111.34 TWD 203.72 TWD 80
Residual Income 24.17 TWD 30.32 TWD 69.96 TWD 76
Rev-Margin DCF 53.21 TWD 97.84 TWD 182.29 TWD 74
All 26 models by family
DCF Models
FCF DCF 67.97 TWD 101.97 TWD 207.99 TWD 38
Owner Earnings 70.56 TWD 150.36 TWD 311.71 TWD 31
5Y Revenue Exit 52.64 TWD 86.15 TWD 156.16 TWD 39
5Y EBITDA Exit 64.93 TWD 110.99 TWD 201.30 TWD 41
5Y P/E Exit 65.37 TWD 138.47 TWD 237.85 TWD 38
10Y Revenue Exit 56.35 TWD 114.34 TWD 150.20 TWD 36
10Y EBITDA Exit 66.75 TWD 140.20 TWD 267.53 TWD 37
10Y P/E Exit 67.06 TWD 141.12 TWD 262.22 TWD 35
Earnings-Based
Graham-Dodd 26.03 TWD 181.53 TWD 254.74 TWD 54
Lynch FV 69.69 TWD 99.56 TWD 129.43 TWD 50
PEG = 1.0 69.69 TWD 99.56 TWD 129.43 TWD 46
EPV 39.27 TWD 44.69 TWD 49.36 TWD 59
Dividend Discount
Gordon GGM 21.14 TWD 42.12 TWD 63.78 TWD 70
DDM Multi-Stage 21.14 TWD 36.40 TWD 44.46 TWD 61
Multiples
P/E Multiple 57.42 TWD 76.56 TWD 95.70 TWD 63
P/S Multiple 40.18 TWD 53.58 TWD 66.97 TWD 58
P/B Multiple 48.81 TWD 65.07 TWD 81.34 TWD 55
EV/EBIT 69.46 TWD 90.96 TWD 112.45 TWD 53
EV/EBITDA 61.78 TWD 80.73 TWD 99.67 TWD 54
EV/Revenue 42.46 TWD 58.54 TWD 74.61 TWD 43
Asset-Based
NCAV (Graham) 11.41 TWD 15.29 TWD 22.83 TWD 50
Growth DCF
Growth DCF 64.13 TWD 111.34 TWD 203.72 TWD 80
Rev-Margin DCF 53.21 TWD 97.84 TWD 182.29 TWD 74
Economic Profit
Residual Income 24.17 TWD 30.32 TWD 69.96 TWD 76
ROIC Compounder 49.66 TWD 72.39 TWD 89.96 TWD 72
Growth Earnings
Growth-Adj P/E 86.95 TWD 124.21 TWD 161.48 TWD 68

Widest divergence: Growth Earnings (124.21 TWD) versus Asset-Based (15.29 TWD). Highest evidence: Growth DCF (80).

Notify me when 1294 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 832M TWD
Revenue growth (YoY) +30.6%
Net margin 18.0%
Return on equity 17.6%
Free cash flow 144M TWD FY2025
P/E ratio 14.8
More key figures
Operating margin 23.1%
EPS (TTM) 3.78 TWD
Dividend yield 4.4%
EPS growth (YoY) +22.1%
Net debt 118M TWD FY2023

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 62/100

Of which business quality 63 · Market factors (momentum, volatility) 39

Profitability 60
Margins and returns on capital today
Quality Growth 31
Are margins and returns improving?
Cashflow 72
Earnings quality: real cash, not paper profit
Fin. Strength 93
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 23
Distance to the 52-week high (market factor)
Net Issuance 66
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Hantech Bio-Technology Co., Ltd., through its subsidiaries, engages in the manufacture, trade in, and distributes biotech foods, health foods, and Traditional Chinese Medicine skincare and beauty products in Taiwan and internationally. The company offers OEM & ODM manufacturer of liquid, jelly, and gel-type health supplements.

Full company description

Hantech Bio-Technology Co., Ltd., through its subsidiaries, engages in the manufacture, trade in, and distributes biotech foods, health foods, and Traditional Chinese Medicine skincare and beauty products in Taiwan and internationally. The company offers OEM & ODM manufacturer of liquid, jelly, and gel-type health supplements. It also provides aluminum foil bag designs; and aluminum foil-packaged beverage production activities. In addition, the company is involved in the manufacture of machinery and equipment; and trade in of health food raw materials. It serves clients across both online and offline channels, including direct sales, micro-businesses, physical stores (pharmacies/drugstores/beauty shops), TV, radio, telemarketing centers, TV shopping, online shopping, and live-stream shopping. Hantech Bio-Technology Co., Ltd. was founded in 2007 and is based in Changhua, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Hantech Bio-Technology Co reported revenue of 779M TWD in FY2025 versus 240M TWD in FY2021, a compound +34.2%/yr. Reported net income was 139M TWD in FY2025, compounding +43.8%/yr from FY2021.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
779M TWD
Latest YoY
+4.0%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+37.0%
Revenue +34.2%/yr
FY21 240M TWD
FY22 303M TWD
FY23 625M TWD
FY24 748M TWD
FY25 779M TWD
Net income +43.8%/yr
FY21 32.6M TWD
FY22 47.5M TWD
FY23 148M TWD
FY24 156M TWD
FY25 139M TWD

Watch 1294: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Hantech Bio-Technology Co Fair Value". https://www.fairvalue-calculator.com/stock/1294

Peer Group

Packaged Foods · 649 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 62 · Above median
Fair Value upside +25% · Above median
Return on equity (TTM) 18% · Top 25%
Return on assets 10% · Top 25%
Net margin (TTM) 18% · Top 25%
Operating margin (TTM) 23% · Top 25%
Revenue growth 31% · Top 25%
Dividend yield (TTM) 4.4% · Top 25%
Debt / equity 0.08× · Higher than median

Valuation Multiples vs Packaged Foods median · lower = cheaper

P/E (TTM) 14.8× · Cheaper than median
P/B 2.46× · Pricier than median
P/S (TTM) 2.45× · Pricier than 75% of peers
P/FCF 0.4× · Cheaper than median
EV/EBITDA 8.8× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 66 · sector 28
FUTURE 100 · sector 20
PAST 70 · sector 27
HEALTH 96 · sector 96
DIVIDEND 89 · sector 47

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
Nestlé India Limited NESTLEIND ₹1,427 ₹362.37 -75%
Britannia Industries Limited BRITANNIA ₹5,413 ₹1,870 -65%
Tata Consumer Products Limited TATACONSUM ₹1,089 ₹327.27 -70%
PT Indofood CBP Sukses Makmur Tbk ICBP 6,650 IDR 15,757 IDR +137%
Samyang Foods Co 003230 1,139,000 KRW 1,010,543 KRW -11%
Patanjali Foods Limited PATANJALI ₹413.80 ₹157.04 -62%
Vietnam Dairy Products Joint Stock Company VNM 58,500 VND 68,259 VND +17%
PT Mayora Indah Tbk, MYOR 1,750 IDR 2,699 IDR +54%
PT Cisarua Mountain Dairy Tbk CMRY 4,490 IDR 4,355 IDR -3%
Nongshim Co 004370 348,500 KRW 530,619 KRW +52%

Compare Hantech Bio-Technology Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Hantech Bio-Technology Co (1294) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 72.52 TWD versus a price of 58.10 TWD, about +25% (undervalued).
What is the fair value of 1294?
Our model-based fair value for Hantech Bio-Technology Co is 72.52 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 58.10 TWD.
What is the quality score of 1294?
Hantech Bio-Technology Co has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Hantech Bio-Technology Co (1294)?
Hantech Bio-Technology Co reported trailing-twelve-month revenue of about 832M TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 1294?
The net profit margin of Hantech Bio-Technology Co is about 18.0%, meaning it keeps roughly 18.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Hantech Bio-Technology Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.